评估替沙格赛定及其在复发或难治性弥漫性大B细胞淋巴瘤治疗中的潜力：迄今的证据。
Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date.
作者信息
Zavras P D, Wang Y, Gandhi A, Lontos K, Delgoffe G M
机构信息
Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tumor Microenvironment Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.
出版信息
Onco Targets Ther. 2019 Jun 11;12:4543-4554. doi: 10.2147/OTT.S177844. eCollection 2019.
Chimeric antigen receptor (CAR) T cells have changed the treatment landscape of relapsed or refractory diffuse large B cell lymphoma. This review focuses on the biology of tisagenlecleucel and the clinical data that support its use in this setting. In addition, we discuss how it compares to other CAR T products, the financial implications for payers, and ongoing trials.
嵌合抗原受体（CAR）T细胞已经改变了复发或难治性弥漫性大B细胞淋巴瘤的治疗格局。本综述重点关注替沙格韦单抗的生物学特性以及支持其在这种情况下使用的临床数据。此外，我们还讨论了它与其他CAR T产品的比较、对支付方的财务影响以及正在进行的试验。
Zotero 插件